JP2021517128A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021517128A5 JP2021517128A5 JP2020546876A JP2020546876A JP2021517128A5 JP 2021517128 A5 JP2021517128 A5 JP 2021517128A5 JP 2020546876 A JP2020546876 A JP 2020546876A JP 2020546876 A JP2020546876 A JP 2020546876A JP 2021517128 A5 JP2021517128 A5 JP 2021517128A5
- Authority
- JP
- Japan
- Prior art keywords
- levodopa
- carbidopa
- secant
- top layer
- therapeutic agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims 34
- 229960004502 levodopa Drugs 0.000 claims 34
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims 33
- 229960004205 carbidopa Drugs 0.000 claims 17
- TZFNLOMSOLWIDK-JTQLQIEISA-N carbidopa (anhydrous) Chemical compound NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 TZFNLOMSOLWIDK-JTQLQIEISA-N 0.000 claims 17
- 239000003814 drug Substances 0.000 claims 16
- 229940124597 therapeutic agent Drugs 0.000 claims 16
- IVTMXOXVAHXCHI-YXLMWLKOSA-N (2s)-2-amino-3-(3,4-dihydroxyphenyl)propanoic acid;(2s)-3-(3,4-dihydroxyphenyl)-2-hydrazinyl-2-methylpropanoic acid Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1.NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 IVTMXOXVAHXCHI-YXLMWLKOSA-N 0.000 claims 9
- 229940052036 carbidopa / levodopa Drugs 0.000 claims 7
- 239000003937 drug carrier Substances 0.000 claims 6
- 208000018737 Parkinson disease Diseases 0.000 claims 5
- 239000003795 chemical substances by application Substances 0.000 claims 5
- 238000001990 intravenous administration Methods 0.000 claims 5
- 230000001225 therapeutic effect Effects 0.000 claims 5
- 239000004480 active ingredient Substances 0.000 claims 4
- 229940015929 carbidopa 12.5 mg Drugs 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 230000004044 response Effects 0.000 claims 4
- 241000255925 Diptera Species 0.000 claims 2
- 230000036470 plasma concentration Effects 0.000 claims 2
- 208000014094 Dystonic disease Diseases 0.000 claims 1
- 206010020751 Hypersensitivity Diseases 0.000 claims 1
- 208000010118 dystonia Diseases 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims 1
- 229940067290 levodopa 50 mg Drugs 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000004043 responsiveness Effects 0.000 claims 1
- 238000011272 standard treatment Methods 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022110134A JP2022133449A (ja) | 2018-03-29 | 2022-07-08 | レボドパ分割用量組成物および使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862650012P | 2018-03-29 | 2018-03-29 | |
| US62/650,012 | 2018-03-29 | ||
| PCT/US2019/024464 WO2019191353A1 (en) | 2018-03-29 | 2019-03-28 | Levodopa fractionated dose composition and use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022110134A Division JP2022133449A (ja) | 2018-03-29 | 2022-07-08 | レボドパ分割用量組成物および使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021517128A JP2021517128A (ja) | 2021-07-15 |
| JP2021517128A5 true JP2021517128A5 (https=) | 2021-08-26 |
Family
ID=68060752
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020546876A Pending JP2021517128A (ja) | 2018-03-29 | 2019-03-28 | レボドパ分割用量組成物および使用 |
| JP2022110134A Pending JP2022133449A (ja) | 2018-03-29 | 2022-07-08 | レボドパ分割用量組成物および使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022110134A Pending JP2022133449A (ja) | 2018-03-29 | 2022-07-08 | レボドパ分割用量組成物および使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US11033521B2 (https=) |
| EP (1) | EP3773532A4 (https=) |
| JP (2) | JP2021517128A (https=) |
| CN (1) | CN111954523A (https=) |
| BR (1) | BR112020017422A2 (https=) |
| WO (1) | WO2019191353A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112020017422A2 (pt) * | 2018-03-29 | 2020-12-22 | Avion Pharmaceuticals , Llc | Composição de dose fracionada de levodopa e uso |
| WO2022044045A1 (en) * | 2020-08-26 | 2022-03-03 | Rubicon Research Private Limited | Modified release formulations of levodopa |
| GB2644236A (en) * | 2024-09-24 | 2026-03-25 | Novumgen Ltd | Orodispersible tablet composition containing carbidopa and levodopa |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5061494A (en) * | 1990-06-14 | 1991-10-29 | The Upjohn Comany | Tri-scored drug tablet |
| AU2005245025B2 (en) | 2004-05-21 | 2010-06-03 | Accu-Break Technologies, Inc. | Pharmaceutical tablets comprising two or more unitary segments |
| CN1960712B (zh) * | 2004-05-21 | 2011-04-20 | 阿库-伯雷克技术公司 | 包含多个片段的刻痕药片 |
| US7838031B2 (en) | 2004-05-21 | 2010-11-23 | Lawrence Solomon | Method of administering a partial dose using a segmented pharmaceutical tablet |
| US8506999B2 (en) | 2005-05-23 | 2013-08-13 | Accu-Break Technologies, Inc. | Pharmaceutical tablets comprising a plurality of segments |
| AR055106A1 (es) * | 2005-08-05 | 2007-08-08 | Osmotica Pharmaceutical Argent | Composicion farmaceutica solida de liberacion extendida que contiene carbidopa y levodopa |
| EP1948138A4 (en) | 2005-11-18 | 2012-07-11 | Accu Break Technologies Inc | SEGMENTED PHARMACEUTICAL DOSAGE FORMS |
| WO2007138086A1 (en) * | 2006-05-31 | 2007-12-06 | Solvay Pharmaceuticals Gmbh | Long term 24 hour intestinal administration of levodopa/carbidopa |
| US20080131492A1 (en) * | 2006-06-23 | 2008-06-05 | Spherics, Inc. | Dosage forms for movement disorder treatment |
| CA2734972C (en) * | 2008-08-22 | 2017-03-28 | Wockhardt Research Centre | An extended release pharmaceutical composition of entacapone or salts thereof |
| PL2432454T3 (pl) * | 2009-05-19 | 2017-10-31 | Neuroderm Ltd | Kompozycje do ciągłego podawania inhibitorów dopa-dekarboksylazy |
| AU2014229127B2 (en) * | 2013-03-13 | 2018-04-05 | Neuroderm Ltd | Method for treatment of parkinson's disease |
| HK1211836A1 (en) * | 2013-03-28 | 2016-06-03 | Omniactive Health Technologies Limited | Neuroprotective effect of carotenoids in brain |
| RU2017120184A (ru) * | 2014-11-28 | 2018-12-28 | БИАЛ - ПОРТЕЛА ЭНД Ка, С.А. | Лекарства для замедления течения болезни паркинсона |
| EP3500246B1 (en) * | 2016-08-18 | 2021-08-04 | Ilko Ilaç Sanayi Ve Ticaret Anonim Sirketi | Antiparkinson tablet formulation with improved dissolution profile |
| BR112020017422A2 (pt) * | 2018-03-29 | 2020-12-22 | Avion Pharmaceuticals , Llc | Composição de dose fracionada de levodopa e uso |
-
2019
- 2019-03-28 BR BR112020017422-0A patent/BR112020017422A2/pt unknown
- 2019-03-28 EP EP19775769.3A patent/EP3773532A4/en not_active Withdrawn
- 2019-03-28 JP JP2020546876A patent/JP2021517128A/ja active Pending
- 2019-03-28 CN CN201980023074.8A patent/CN111954523A/zh active Pending
- 2019-03-28 WO PCT/US2019/024464 patent/WO2019191353A1/en not_active Ceased
- 2019-12-18 US US16/719,203 patent/US11033521B2/en active Active
-
2021
- 2021-03-31 US US17/219,253 patent/US11439613B2/en active Active
-
2022
- 2022-07-08 JP JP2022110134A patent/JP2022133449A/ja active Pending
- 2022-08-26 US US17/896,808 patent/US11819485B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7442095B2 (ja) | ベータ－ヒドロキシブチレート及びブタンジオールのｓ－エナンチオマー並びにその使用方法 | |
| ES2214729T3 (es) | Acido 9-cis-retinoico para enfermedades inmunes inducidas por celulas. | |
| JP2023040166A (ja) | カンナビジオールによる脆弱ｘ症候群の処置 | |
| WO2005065069A3 (en) | Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease | |
| JP2021527092A5 (https=) | ||
| HUE035105T2 (en) | A composition comprising nicotine and opipramole and its use | |
| CN106999467A (zh) | 治疗认知减退的方法 | |
| US11826321B2 (en) | Cyclobenzaprine treatment for agitation, psychosis and cognitive decline in dementia and neurodegenerative conditions | |
| JP2021517128A5 (https=) | ||
| WO2024166059A1 (en) | Compositions comprising n,n-dimethyltryptamine, optionally in combination with n-acylethanolamines and uses thereof | |
| JP2016505050A5 (https=) | ||
| ES2677474T3 (es) | Un metabolito de iloperidona para uso en el tratamiento de trastornos psiquiátricos | |
| US20250302773A1 (en) | Compositions comprising meai and n-acylethanolamines and uses thereof | |
| CN120659608A (zh) | 用于治疗癌症的tead抑制剂和kras g12d抑制剂组合 | |
| JP2024531799A5 (https=) | ||
| FR2647784A1 (fr) | Association de vitamine a a dose physiologique et de differents principes actifs ayant une activite therapeutique | |
| CN104906501A (zh) | 治疗银屑病的中药组分组合物 | |
| US11826326B2 (en) | Benzoic acid or a salt and derivative thereof for use in preventing or treating depression | |
| CN108478581A (zh) | 防治运动病、梅尼埃病的药物及托伐普坦的医药用途 | |
| EP4665327A1 (en) | Compositions comprising 3,4-methylenedioxymethamphetamine, optionally in combination with n-acylethanolamines, and uses thereof | |
| JP2018177773A (ja) | 医薬 | |
| EP3725312A1 (en) | New chemical compound containing active enantiomer s-(-) ketorolac tromethamine for the treatment of pain | |
| JP2024524288A5 (https=) | ||
| CN101327196B (zh) | 剂型和施药方法 | |
| JP2023507764A5 (https=) |